

Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation

David H. Birnie, M.D., Jeff S. Healey, M.D., George A. Wells, Ph.D., Atul Verma, M.D., Anthony S. Tang, M.D., Andrew D. Krahn, M.D., Christopher S. Simpson, M.D., Felix Ayala-Paredes, M.D., Benoit Coutu, M.D., Tiago L.L. Leiria, M.D., and Vidal Essebag, M.D., Ph.D., for the BRUISE CONTROL Investigators*

ABSTRACT

BACKGROUND

Many patients requiring pacemaker or implantable cardioverter-defibrillator (ICD) surgery are taking warfarin. For patients at high risk for thromboembolic events, guidelines recommend bridging therapy with heparin; however, case series suggest that it may be safe to perform surgery without interrupting warfarin treatment. There have been few results from clinical trials to support the safety and efficacy of this approach.

METHODS

We randomly assigned patients with an annual risk of thromboembolic events of 5% or more to continued warfarin treatment or to bridging therapy with heparin. The primary outcome was clinically significant device-pocket hematoma, which was defined as device-pocket hematoma that necessitated prolonged hospitalization, interruption of anticoagulation therapy, or further surgery (e.g., hematoma evacuation).

RESULTS

The data and safety monitoring board recommended termination of the trial after the second prespecified interim analysis. Clinically significant device-pocket hematoma occurred in 12 of 343 patients (3.5%) in the continued-warfarin group, as compared with 54 of 338 (16.0%) in the heparin-bridging group (relative risk, 0.19; 95% confidence interval, 0.10 to 0.36; $P < 0.001$). Major surgical and thromboembolic complications were rare and did not differ significantly between the study groups. They included one episode of cardiac tamponade and one myocardial infarction in the heparin-bridging group and one stroke and one transient ischemic attack in the continued-warfarin group.

CONCLUSIONS

As compared with bridging therapy with heparin, a strategy of continued warfarin treatment at the time of pacemaker or ICD surgery markedly reduced the incidence of clinically significant device-pocket hematoma. (Funded by the Canadian Institutes of Health Research and the Ministry of Health and Long-Term Care of Ontario; BRUISE CONTROL ClinicalTrials.gov number, NCT00800137.)

From the University of Ottawa Heart Institute, Ottawa (D.H.B., G.A.W., A.S.T.); Population Health Research Institute, Hamilton, ON (J.S.H.); Southlake Regional Health Centre, Newmarket, ON (A.V.); Island Medical Program, University of British Columbia, Vancouver (A.S.T.); University of British Columbia, Vancouver (A.D.K.); Queen's University and Kingston General Hospital, Kingston, ON (C.S.S.); Université de Sherbrooke, Sherbrooke, QC (F.A.-P.); Hôpital Hôtel-Dieu Centre Hospitalier de l'Université de Montréal, Montreal (B.C.); and McGill University Health Centre and Hôpital du Sacré-Coeur de Montréal, Montreal (V.E.) — all in Canada; and Instituto de Cardiologia Fundação Universitaria Cardiologia, Porto Alegre, Brazil (T.L.L.L.). Address reprint requests to Dr. Birnie at the University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON K1Y 4W7, Canada, or at dbirnie@ottawaheart.ca.

*Investigators in the Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial (BRUISE CONTROL) are listed in the Supplementary Appendix, available at NEJM.org.

This article was published on May 9, 2013, at NEJM.org.

N Engl J Med 2013;368:2084-93.

DOI: 10.1056/NEJMoa1302946

Copyright © 2013 Massachusetts Medical Society.